Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases

Table 5 Clinical and biochemical characteristics in all study population in relation to their fibrosis staging (mean±SD)

Characteristics	NAFLD		CH
	Normal-mildfibrosis	Moderate-severefibrosis	Normal-mildfibrosis	Moderate-severefibrosis
IRI	3.9±3.0	3.9±1.6	1.2±0.7	1.9±0.8
BMI	31±5.0	34±6.7	23.6±1.5	24±3.9
Protein C (%)	128±40	129±36	96±14b	88±13
Protein S (%)	100±22d	84±16	96±19	77±16
Antithrombin III	110±17	116±8.9	111±3.7	101±7.4
APC ratio	2.3±0.1	2.2±0.1	2.01±0.3	2.3±0.3
Lupus anticoagulant	1.0±0.09	1.0±0.09	0.99±0.4	0.99±0.8
PT (%)	105±13	107±13	103±22	97±10
PTT (s)	32±5	29.5±2.0	32±4.6	30±4.3
Fibrinogen, mg/dL	306±57	337±57	290±29	314±64
PT mutation 20210A	Normal	Normal	Normal	Normal
Factor V Leiden	Normal	Normal	Normal	Normal
MTHFR (n)	One mutation	Normal	Normal	Normal
Platelets	244±43	237±47	242±36	225±44
Activity score	5.5±4.2	7.5±2.3	8.0±5.0	12.8±4.3

^aP<0.01, CH mild fibrosis vs CH severe fibrosis;

^bP<0.01, NAFLD mild fibrosis vs NAFLD severe fibrosis.